In the category of COVID innovation, Greensboro-based Qorvo Biotechnologies has received a $4.1 million follow-on contact from the National Institutes of Health to support its COVID-related diagnostic test platform. The agreement is through the NIH’s Rapid Acceleration of Diagnostics initiative.